The project to manufacture the anti-Covid19 Sinopharm vaccine will see the light of day at the beginning of next December, informed sources confirmed to MoroccoLatestNews, specifying that Morocco will begin with the production of five million doses of the Sinopharm vaccine in Sothema laboratories.
The result of a public-private partnership, this project, which plans to start in the short term with a monthly production capacity of 5 million doses of anti-Covid19 vaccines per month, has started to begin on schedule.
The CEO of the Sothema group, Lamia Tazi, told MoroccoLatestNews that “the date scheduled for the launch of vaccine manufacturing is maintained until now”.
Tazi clarified that “all regulatory procedures are continuing and nothing has changed regarding the process.”
For his part, Saïd Afif, member of the National Vaccination Commission, revealed that the state will start manufacturing the anti-Covid19 Sinopharm vaccine from next December, in the laboratories of the Sothema company.
This is the date set by the government and the company specializing in the pharmaceutical industry months ago as part of the agreements signed in early July before King Mohammed VI.
Note that a contract was sealed for the provision to the Moroccan State of aseptic filling facilities of the Moroccan Therapeutics Company (Sothema) for the manufacture of the anti-Covid19 Sinopharm vaccine between the Moroccan State and Sothema, signed by Khalid Ait Taleb, and Sothema CEO Lamia Tazi.
This project of an envelope of 500 million dollars, approximately 421 million euros, should make it possible, in addition to meeting the needs of the national vaccination campaign, to make Morocco the pharmacist of Africa.
Beyond strengthening Morocco’s health sovereignty, the Sinopharm anti-Covid19 vaccine manufacturing project will make the Kingdom a health security provider within its regional and continental environment.